CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case seriesJanina Auth, Christina Bergmann, Tobias Bäuerle et al.|The Lancet Rheumatology|2024Cited by 96
Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational studyMelanie Hagen, Georg Schett, Fabian Müller et al.|The Lancet Rheumatology|2025Cited by 71
BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cellsFabian Müller, Ricardo Grieshaber‐Bouyer, Andreas Wirsching et al.|Nature Medicine|2025Cited by 60
Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphomaFabian Müller, Simon Völkl, Melanie Hagen et al.|Blood|2025Cited by 27
Treatment of CNS systemic lupus erythematosus with CD19 CAR T cellsMelanie Hagen, Georg Schett, Fabian Müller et al.|The Lancet|2024Cited by 26